Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Junya
J
Kuroda
Tsutomu
T
Kobayashi
Yasuhiko
Y
Tsutsumi
Mio
M
Yamamoto
Muneo
M
Ohshiro
Nana
N
Sasaki
Yuji
Y
Shimura
Shinsuke
S
Mizutani
Hisao
H
Nagoshi
Miki
M
Kiyota
Ryuko
R
Nakayama
Hitoji
H
Uchiyama
Yosuke
Y
Matsumoto
Shigeo
S
Horiike
Chihiro
C
Shimazaki
Masafumi
M
Taniwaki
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications / Q000188:drug therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D011719:Pyrazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D016879:Salvage Therapy; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone